Gastrointestinal Agents

• 

  Subject Areas on Research

  • A Programme for Risk Assessment and Minimisation of Progressive Multifocal Leukoencephalopathy Developed for Vedolizumab Clinical Trials. 
  • A cost analysis of outpatient care for patients with Barrett's esophagus in a managed care setting. 
  • A phase III double-blind randomised study of rectal sucralfate suspension in the prevention of acute radiation proctitis. 
  • A pilot phase II randomized, cross-over, double-blinded, controlled efficacy study of octreotide versus hyoscine hydrobromide for control of noisy breathing at the end-of-life. 
  • A pressing situation. 
  • A randomized, double-blind, placebo-controlled trial of porcine versus synthetic secretin for reducing symptoms of autism. 
  • Abdominal migraine: prophylactic treatment and follow-up. 
  • Acute histologic effects of extraesophageal reflux on vocal fold healing. 
  • Advances in the nontransplant medical and surgical management of intestinal failure. 
  • Adverse drug events in high risk older outpatients. 
  • Alginate therapy is effective treatment for gastroesophageal reflux disease symptoms: a systematic review and meta-analysis. 
  • Alvimopan Provides Additional Improvement in Outcomes and Cost Savings in Enhanced Recovery Colorectal Surgery. 
  • Bombesin inhibits alveolarization and promotes pulmonary fibrosis in newborn mice. 
  • Celecoxib (celebrex) increases canine lower esophageal sphincter pressure. 
  • Clinical trial: asimadoline in the treatment of patients with irritable bowel syndrome. 
  • Covert hepatic encephalopathy: not as minimal as you might think. 
  • Differential effect of HERG blocking agents on cardiac electrical alternans in the guinea pig. 
  • Double-blind, placebo-controlled, randomized trial of octreotide in malignant bowel obstruction. 
  • Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening. 
  • Emerging treatments for ulcerative colitis: a systematic review. 
  • Erythromycin lacks colon prokinetic effect in children with functional gastrointestinal disorders: a retrospective study. 
  • Erythromycin vs metoclopramide for facilitating gastric emptying and tolerance to intragastric nutrition in critically ill patients. 
  • Extra-intestinal Hodgkin's lymphoma in a Crohn's disease patient on long-term azathioprine and infliximab therapy. 
  • Factors Associated With Histologic Response in Adult Patients With Nonalcoholic Steatohepatitis. 
  • Gastric motility function in critically ill patients tolerant vs intolerant to gastric nutrition. 
  • Hepatocellular carcinoma occurring in a patient with Crohn's disease treated with both azathioprine and infliximab. 
  • Inflammatory Bowel Disease Patients' Willingness to Accept Medication Risk to Avoid Future Disease Relapse. 
  • Infliximab Reduces Endoscopic, but Not Clinical, Recurrence of Crohn's Disease After Ileocolonic Resection. 
  • Infliximab maintenance therapy for fistulizing Crohn's disease. 
  • Intravenous synthetic secretin reduces the incidence of pancreatitis induced by endoscopic retrograde cholangiopancreatography. 
  • Medication prescribing practices for older prisoners in the Texas prison system. 
  • Menetrier's disease treated with octreotide long-acting release. 
  • Multiple endocrine neoplasia type 1 manifesting with chronic and persistent diarrhea. 
  • Osteoporosis piece of multi-morbidity puzzle in geriatric care. 
  • Quantifying women's stated benefit-risk trade-off preferences for IBS treatment outcomes. 
  • Successful treatment of chronic hepatitis C with pegylated interferon, ribavirin, and infliximab in a patient with Crohn's disease. 
  • Suppression of renal disease and mortality in the female NZB x NZW F1 mouse model of systemic lupus erythematosus (SLE) by chenodeoxycholic acid. 
  • The Impact of Risk Factors of Chronic Pancreatitis on Secretin Pancreatic Function Testing: Results of a 20-Year Study. 
  • Use and Safety of Erythromycin and Metoclopramide in Hospitalized Infants. 
  • Using the incremental net benefit framework for quantitative benefit-risk analysis in regulatory decision-making--a case study of alosetron in irritable bowel syndrome.